Asset Details
Do you wish to reserve the book?
Comparative effect of different corticosteroids in severe community-acquired pneumonia: a network meta-analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Comparative effect of different corticosteroids in severe community-acquired pneumonia: a network meta-analysis
Do you wish to request the book?
Comparative effect of different corticosteroids in severe community-acquired pneumonia: a network meta-analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Comparative effect of different corticosteroids in severe community-acquired pneumonia: a network meta-analysis
2025
Overview
Background and objectives
Severe community-acquired pneumonia (CAP) is a potentially fatal pulmonary disease. Although studies have investigated the efficacy and safety of corticosteroids for severe CAP, the results remain inconsistent. Moreover, there is a lack of sufficient evidence to rank the effects of different types of corticosteroids. The aim of this study is to elucidate the effects of different corticosteroids in patients with severe CAP.
Methods
We searched PubMed, Embase, Cochrane Library, and Web of Science comprehensively, encompassing all publications with a search deadline of March 31, 2024. Only randomized controlled trials (RCTs) involving the treatment of severe CAP with corticosteroids were included. The primary efficacy outcome was all-cause mortality, secondary efficacy outcome was mechanical ventilation (MV), and safety outcome was the incidence of serious adverse events (SAEs).
Results
A total of 11 studies, involving 2042 participants, compared four corticosteroids (hydrocortisone, dexamethasone, prednisolone, methylprednisolone). The included trials were all corticosteroid versus placebo comparisons, resulting in a star-shaped network. Among the four corticosteroids, only hydrocortisone was significantly more effective at reducing mortality than placebo (RR, 0.35; 95% CrI, 0.14–0.64). Additionally, hydrocortisone reduced the need for MV (RR, 0.73; 95% CrI, 0.51–0.93). Furthermore, subgroup analysis indicated that low-to-moderate doses, short-course corticosteroids are associated with a reduction in both mortality and the need for MV.
Conclusion
In the evaluated corticosteroid regimen, hydrocortisone might be an effective measure to reduce all-cause mortality in patients with severe CAP.
Clinical trial number
The present study is a meta-analysis and literature review, therefore clinical trial number is not applicable.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
Adrenal Cortex Hormones - therapeutic use
/ Bias
/ China
/ Community-Acquired Infections - drug therapy
/ Community-Acquired Infections - mortality
/ Community-Acquired Pneumonia
/ Dexamethasone - therapeutic use
/ Glucocorticoids - therapeutic use
/ Humans
/ Hydrocortisone - therapeutic use
/ Medicine
/ Methylprednisolone - therapeutic use
/ Multiple organ dysfunction syndrome
/ Patients
/ Placebos
/ Pneumology/Respiratory System
/ Prednisolone - therapeutic use
/ Randomized Controlled Trials as Topic
/ Respiration, Artificial - statistics & numerical data
/ Software
/ Steroids
